Clinical Trial Update: SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating the triple combo of trabectedin, ipilimumab, and nivolumab in previously treated advanced or metastatic soft tissue…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma
• Soft-tissue Sarcoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)
• Yondelis (trabectedin)

Snippet

Sponsor: Sarcoma Oncology Research Center, LLC | Conditions: Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: RECRUITING